Back to results
US 11,186,842 B2Granted
Complement component iRNA compositions and methods of use thereof
AssigneeAlnylam Pharmaceuticals, Inc.
InventorsAnna Borodovsky, Brian Bettencourt
Life of this patent
Estimating the term…
Abstract
The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the complement factor B (CFB) gene, the complement component C3 gene, and the complement component C9 gene and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of CFB, C9 and/or C3 and to treat subjects having a complement component-associated disease, e.g., paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Claims18
A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement factor B (CFB) in a cell,
- wherein the dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region,
- wherein said sense strand comprises the nucleotide sequence of 5′-GCUGUGGUGUCUGAGUACUUU-3′ (SEQ ID NO:45), and said antisense strand comprises the nucleotide sequence of 5′ AAAGUACUCAGACACCACAGCCC-3′ (SEQ ID NO:76),
- wherein substantially all of the nucleotides of said sense strand comprise a modification selected from the group consisting of a 2′-O-methyl modification and a 2′-fluoro modification,
- wherein said sense strand comprises two phosphorothioate internucleotide linkages at the 5′-terminus,
- wherein substantially all of the nucleotides of said antisense strand comprise a modification selected from the group consisting of a 2′-O-methyl modification and a 2′-fluoro modification,
- wherein said antisense strand comprises two phosphorothioate internucleotide linkages at the 5′-terminus and two phosphorothioate internucleotide linkages at the 3′-terminus, and
- wherein said sense strand is conjugated to one or more GalNAc derivatives attached through a branched bivalent or trivalent linker at the 3′-terminus.
4 more elements
Dependencies are inferred from the claim text.